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Abstract
Background: For women who have a caesarean section in their preceding pregnancy, two care
policies for birth are considered standard: planned vaginal birth and planned elective repeat
caesarean. Currently available information about the benefits and harms of both forms of care are
derived from retrospective and prospective cohort studies. There have been no randomised trials,
and recognising the deficiencies in the literature, there have been calls for methodologically
rigorous studies to assess maternal and infant health outcomes associated with both care policies.
The aims of our study are to assess in women with a previous caesarean birth, who are eligible in
the subsequent pregnancy for a vaginal birth, whether a policy of planned vaginal birth after
caesarean compared with a policy of planned repeat caesarean affects the risk of serious
complications for the woman and her infant.
Methods/Design: Design: Multicentred patient preference study and a randomised clinical trial.
Inclusion Criteria: Women with a single prior caesarean presenting in their next pregnancy with a
single, live fetus in cephalic presentation, who have reached 37 weeks gestation, and who do not
have a contraindication to a planned VBAC.
Trial Entry & Randomisation: Eligible women will be given an information sheet during pregnancy,
and will be recruited to the study from 37 weeks gestation after an obstetrician has confirmed
eligibility for a planned vaginal birth. Written informed consent will be obtained. Women who
consent to the patient preference study will be allocated their preference for either planned VBAC
or planned, elective repeat caesarean. Women who consent to the randomised trial will be
randomly allocated to either the planned vaginal birth after caesarean or planned elective repeat
caesarean group.
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Treatment Groups: Women in the planned vaginal birth group will await spontaneous onset of
labour whilst appropriate. Women in the elective repeat caesarean group will have this scheduled
for between 38 and 40 weeks.
Primary Study Outcome: Serious adverse infant outcome (death or serious morbidity).
Sample Size: 2314 women in the patient preference study to show a difference in adverse neonatal
outcome from 1.6% to 3.6% (p = 0.05, 80% power).
Clinical Trial Registration: ISCTRN5397431
Background
Caesarean section is a common surgical procedure per-
formed on women worldwide. The rate of caesarean sec-
tion in most developed countries around the world has
continued to increase over recent years, and currently
accounts for 21.3% of all births in the United Kingdom,
23% in Northern Ireland [1], 23.3% in Australia [2], and
26% in the United States [3]. Caesarean section rates in
South America are reported to be even higher, reaching in
excess of 50% in some private hospitals in Chile, Argen-
tina, Brazil and Paraguay [4]. Many reasons have been
suggested to account for the increase in caesarean section
observed over recent years, including the increasing use of
electronic fetal heart rate monitoring during labour, a
reduction in the training available to obstetricians in both
operative vaginal births and vaginal breech births, in addi-
tion to fears of litigation [5].
Repeat caesarean section is the most common primary
indication for a woman undergoing a repeat caesarean,
accounting for 28% of births in the United Kingdom [1]
and over 40% of births in the United States [6]. In South
Australia, the main reason (56.6%) for women having an
elective caesarean is that they have had a previous caesar-
ean section, and 13.9% of emergency caesareans per-
formed are in women who have had a previous caesarean
[7]. Figures from the United States in 2003 indicate a
repeat caesarean section rate of 89.4%, with a similar pro-
portion of caesareans (88.7%) occurring in women con-
sidered to be 'low-risk' [8].
Many studies have examined the reasons for the increase
in the proportion of caesarean births observed, assessing
population characteristics, variations in clinician practice
[9], available resources, women's childbirth preferences
[9-12], and the views of health care practitioners [13-15].
The American College of Obstetricians and Gynecologists
issued a consensus statement supporting vaginal birth
after caesarean section as a "safe and acceptable" care
option, in an attempt to address the increasing caesarean
section rate, and increase the proportion of women
attempting vaginal birth after caesarean [16].
While there is considerable variation in the proportion of
women who are offered and attempt VBAC, successful
rates of between 56% and 80% are reported in the litera-
ture [9,13,17,18]. British figures indicate that among
women with a prior caesarean section, 33% will success-
fully achieve vaginal birth in a subsequent pregnancy,
although again there was considerable variation across
institutions, ranging from 6% to 64% [1]. Rates of
planned VBAC across sub-Saharan Africa are reported
between 54 and 97%, with successful vaginal birth being
achieved in 63 to 84% of women [19].
Despite widespread attempts to increase the proportion of
women with a previous caesarean who attempt VBAC
[20], the number of women attempting VBAC has
declined markedly. This is highlighted by data from the
United States, indicating a fall in the number of women
attempting VBAC from 28.3% in 1996 to 12.7% in 2002
[3]. Further contributing to this decline in the proportion
of women attempting VBAC are recent literature reports
highlighting an increase in both maternal and infant risks
associated with VBAC, including uterine rupture [21-23]
and perinatal death [24]. These reports may have acceler-
ated the declining trend in VBAC rates [3].
Public interest and debate over the relative safety of vagi-
nal birth after caesarean continues, with calls from key
international agencies for better quality evidence [25].
Benefits and harms associated with vaginal birth after 
caesarean and elective repeat caesarean section
Both repeat elective caesarean section and VBAC are asso-
ciated with benefits and harms. Repeat elective caesarean
birth is associated with an increase in the risk of maternal
complications such as bleeding, need for blood transfu-
sion, infection, damage to the bladder and bowel, and
deep venous thrombosis. As the number of caesarean
births for each individual woman increases, so does the
difficulty in performing surgery due to adhesions, and the
risk of damage to the bladder or bowel at the time of sur-
gery. There may also be difficulties in conceiving a further
child or the development of placenta praevia or placenta
accreta/percreta [26]. Infants born by caesarean may
develop transient tachypnoea of the newborn, the risks ofBMC Pregnancy and Childbirth 2007, 7:17 http://www.biomedcentral.com/1471-2393/7/17
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this relating to the use of general anaesthesia and gesta-
tional age at birth [27,28].
One uncommon, but potentially serious complication
associated with a prior uterine surgery (including a previ-
ous caesarean section) is that of uterine rupture which
may occur prior to the onset of labour, or during labour.
Any vaginal birth may be associated with a non-reassuring
fetal heart rate assessment, or failure to progress, both of
which may require birth by emergency caesarean section.
Emergency caesarean in labour is associated with an
increased chance of infection, bleeding, and deep venous
thrombosis, when compared with both vaginal birth and
elective caesarean birth. Any vaginal birth may be associ-
ated with trauma to the woman's perineum and may be
associated with longer-term problems, including pelvic
floor weakness contributing to symptoms of prolapse and
incontinence.
In searching the literature in preparation of a Cochrane
Review [29] to evaluate the benefits and harms of vaginal
birth after caesarean and elective repeat caesarean section
for health outcomes for women and infants, in excess of
2000 case series and cohort studies, and five systematic
reviews [19,25,30-35] were identified. The magnitude of
risks for both repeat elective caesarean section and vaginal
birth after caesarean section are best summarized through
the published systematic reviews. While the methodology
of each of the meta-analyses was well defined, the magni-
tude of the clinical outcomes reported varied considerably
(see Table 1).
The most comprehensive of the systematic review was
conducted by Guise and colleagues, in which 180 studies
were identified, that compared the benefits and harms of
a trial of labour and an elective repeat caesarean section
[25,34,35]. In an assessment of study quality, the conclu-
sion reached indicated the literature to be 'significantly
flawed', with comparisons between studies hampered by
poor standards of reporting, inconsistent definitions of
outcomes, considerable variation in reporting of impor-
tant clinical outcomes, and lack of comparability of
groups, specifically it often being unclear whether women
included in the elective repeat caesarean group were truly
Table 1: Clinical outcomes from the five identified systematic reviews
Outcome Trial of Labour Elective Repeat Caesarean
Febrile Morbidity
- Rosen [32,33] 9.6/100 17.3/100
- Boulvain [19] Not Separated Not Separated
- Mozurkewich [31] 4.3/100 5.5/100
- Guise [25] 8.6–9.7/100 6.6–6.8/100
- Dodd [30] Not Reported Not Reported
Uterine Rupture/Dehiscence
- Rosen [32,33] 1.8/100 1.9/100
- Boulvain [19] Not Separated Not Separated
- Mozurkewich [31] 3.9/1000 1.6/1000
- Guise [25] 2.7/1000 Not Reported
- Dodd [30] 1.2/100 0
Low Apgar Score
- Rosen [32,33] 2.4/100 1.6/100
- Boulvain [19] Not Separated Not Separated
- Mozurkewich [31] 2.2/100 9/1000
- Guise [25] Not Reported Not Reported
- Dodd [30] 4.2/100 8/1000
Perinatal Death
- Rosen [32,33] 1.8/100 1/100
- Boulvain [19] Not Separated Not Separated
- Mozurkewich [31] 5.8/1000 3.4/1000
- Guise [25] 1.3–9/1000 1/10 000–5/1000
- Dodd [30] 7.7/1000 0
Maternal Death
- Rosen [32,33] 2.8/1000 2.4/10 000
- Boulvain [19] Not Separated Not Separated
- Mozurkewich [31] 0 0
- Guise [25] Not Reported Not Reported
- Dodd [30] 0 0BMC Pregnancy and Childbirth 2007, 7:17 http://www.biomedcentral.com/1471-2393/7/17
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eligible to attempt vaginal birth after caesarean
[25,34,35].
The recommendations of the Guise systematic review
highlighted the need for further research that 'should
focus on conducting methodologically rigorous studies to
provide direct evidence regarding the relative benefits and
harms of VBAC and ERC. If randomised trials are not
done, good-quality studies of VBAC versus ERC must pay
attention to comparability of the groups, specificity of the
intervention, and standard outcome measures'[25,34,35].
The National Institute of Child Health and Human Devel-
opment Maternal Fetal Medicine Units Network recently
conducted a large prospective observational study across
19 centres in the United States [36]. A total of 33,699
women with a prior caesarean birth were involved in the
study, of whom 17,898 (53.1%) attempted VBAC, and
15,801 (46.9%) underwent elective repeat caesarean sec-
tion. The observed rate of symptomatic uterine scar rup-
ture among women attempting a VBAC was 0.7%. The
absolute risk of infant hypoxic ischaemic encephalopathy
was 0.46 per 1,000 women attempting a VBAC at term.
The authors concluded that an attempted VBAC was asso-
ciated with an increase risk of perinatal morbidity and
mortality when compared with elective repeat caesarean
section, although the absolute risks remained small [36].
Women's preferences for mode of birth
Women's expectations for birth and mode of birth prefer-
ences are influenced not only by knowledge of the poten-
tial benefits and risks but also personal and social factors.
In the caesarean section audit conducted in the United
Kingdom, 45% of women with a previous caesarean indi-
cated a preference for vaginal birth in a subsequent preg-
nancy, while 20% preferred an elective repeat caesarean.
While a further 27% of women had their preference deter-
mined by medical factors, only 6.2% of women expressed
no preference for mode of birth [1]. In a survey of recent
mothers who had given birth by caesarean section, 63% of
women indicated a preference for their subsequent mode
of birth (either VBAC or repeat elective caesarean section),
with these preferences for care being formed within six
months of the index caesarean birth [37].
In a systematic review, Eden and colleagues [38] identified
that women with a previous vaginal birth were more likely
to select a trial of labour in a subsequent pregnancy when
compared with women who had not had a previous vagi-
nal birth. The cited reasons included ease of recovery and
need to return quickly to ongoing family responsibilities,
rather than concerns primarily for the woman's own
safety or that of her infant [38]. Any future research
designed to influence the rate of planned vaginal birth
after caesarean section must include an assessment of
women's views, and an evaluation of women's process of
decision making [25].
Justification for a randomised trial and patient preference 
study of planned VBAC versus planned repeat caesarean
To date, there have been no randomised controlled trials
comparing VBAC with elective repeat caesarean section
[29], and the observational studies currently available
have limitations. Although the randomised controlled
trial is regarded as the 'gold standard' research methodol-
ogy for assessing the effects of health care interventions
[39], some research questions cannot be fully answered
using this design, particularly in situations where patients
may have strong treatment preferences and thus decline
randomisation [40,41].
Patient preferences have been effectively incorporated
into a prospective cohort study design previously [42].
The inclusion of women with clear preferences for treat-
ment improves generalisability of the study results [43],
and this design has been used successfully in other studies
relating to women's health issues [44,45].
Previous cohort studies relating to options for birth after
a previous caesarean have been criticised for their striking
methodological deficiencies, with strong recommenda-
tion that future studies avoid the following pitfalls: lack of
comparability of groups, specifically the ERC group not
guaranteed to be eligible for VBAC; failure to consider
other important baseline comparability factors, poor spe-
cificity of the intervention and the importance of co-inter-
ventions, and lack of precise and standard outcome
measures [25]. In addition the recommendation was that
future studies should assess women's views of care and
evaluate women's process of decision-making [25]. To
specifically address these recommendations, the current
research utilises rigorous methodology, using a 'restricted'
prospective cohort study and a randomised clinical trial.
A 'restricted' prospective cohort study design utilises the
rigour of recruitment, treatment schedules and follow up
of the randomised controlled trial [46]. Adoption of this
methodology has not been shown to systematically over-
estimate the magnitude of the treatment effects when
compared with the results of randomised controlled trials
[47]. Features of importance in the restrictive cohort
design [46] include the identification of a 'zero time' for
determining a woman's eligibility and baseline features;
use of inclusion and exclusion criteria similar to those of
clinical trials; adjustment for differences in base-line sus-
ceptibility to the outcomes; and the use of statistical meth-
ods (eg intention-to-treat analysis) similar to randomised
controlled trials.BMC Pregnancy and Childbirth 2007, 7:17 http://www.biomedcentral.com/1471-2393/7/17
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Using this methodology, we will conduct a, patient pref-
erence study and a randomised clinical trial to compare
the benefits and risks of a planned VBAC with planned
elective, repeat caesarean. Eligible women who consent to
be randomised will be entered into the randomised trial.
Eligible women who decline randomisation and consent
to be entered into the patient preference study will choose
their treatment preference and follow the study protocol
for that treatment group.
Hypotheses
The primary null hypothesis is that for women who meet
the accepted eligibility criteria for planned VBAC, there is
no difference in the risk of death or serious adverse out-
come up to the time of primary hospital discharge for the
infant in women who have a planned VBAC compared
with a planned elective repeat caesarean section.
The secondary null hypotheses are that for women, who
meet the accepted, eligibility criteria for a planned VBAC,
for women who have a planned VBAC compared with
planned elective repeat caesarean there is no difference in




Multicentred patient preference study and a randomised
clinical trial.
Inclusion Criteria
Women with a single prior caesarean presenting in their
next pregnancy with a single, live fetus in cephalic presen-
tation, who have reached 37 weeks gestation, and who do
not have a contraindication to a planned VBAC are eligi-
ble.
Exclusion Criteria
Women with any of the following are ineligible: more
than one prior caesarean birth, vertical, inverted T or
unknown uterine incision, previous uterine rupture, pre-
vious uterine surgery (including hysterotomy or previous
myomectomy involving entry of the uterine cavity or
excessive myometrial dissection), previous uterine perfo-
ration, multiple pregnancy, any contraindication to vagi-
nal birth (including placenta praevia, transverse lie, active
genital herpes infection), cephalo-pelvic disproportion as
judged by the clinician, lethal congenital anomaly, fetal
anomaly associated with mechanical difficulties at birth
(such as hydrops, fetal ascites, hydrocephalus, ompha-
locele or cystic hygroma).
The inclusion/exclusion criteria are based on guidelines
recommended by the Society of Obstetricians and Gyne-
cologists of Canada [48], American College of Obstetrics
and Gynecology [16], the Institute for Clinical Systems
Improvement [49], and the National Institute for Clinical
Effectiveness [50], UK.
Trial Entry
Ethical approval for this study has been obtained from
each of the participating collaborating hospitals. Women
at the collaborating hospitals who may be eligible for the
study will be given the study information sheet during
their pregnancy and a copy of the Royal Australian and
New Zealand College of Obstetricians and Gynaecologists
information pamphlets 'Vaginal birth after caesarean sec-
tion – a guide for women' and 'Caesarean birth' [51,52].
Women will discuss their birth options with their primary
caregiver.
Written information that contains a brief summary of the
benefits and risks of vaginal birth and elective repeat cae-
sarean given to women with a prior caesarean has been
shown to be as effective as a more detailed prenatal edu-
cation and support program on the proportion of women
having a planned VBAC [53]. To maximise the likelihood
that women will receive their planned choice for birth care
or care allocated at randomisation, eligible women can be
recruited from 37 weeks gestation onwards. As it is impor-
tant to ensure that women in the 'restricted' prospective
study who choose a planned elective repeat caesarean
would have been eligible for a planned VBAC [25] an
obstetrician will confirm that the woman is eligible for a
planned vaginal birth at the time of study entry.
After the woman consents to be in the patient preference
study or the randomised trial, and written, informed con-
sent given to a member of the research team, entry details
will be recorded on the entry form. During a short tele-
phone call to the central telephone randomisation service,
information will be given to check eligibility, to assist in
follow-up, and to assist in the analysis of results. An inves-
tigator not involved with clinical care will prepare the ran-
domisation schedule for the randomised study.
Stratification at randomisation will be by collaborating
centre, and previous successful vaginal birth.
Women consenting to the randomised trial will be ran-
domised to either planned vaginal birth after caesarean or
planned elective repeat caesarean, from the computer ran-
domisation schedule and given a study number. Once all
entry details are given at telephone recruitment and eligi-
bility is confirmed, women consenting to the patient pref-
erence study will be asked their preference for either
planned VBAC or planned, elective repeat caesarean, and
given a study number.
At study entry, socio-demographic characteristics of the
woman, details of previous caesarean section, and infor-BMC Pregnancy and Childbirth 2007, 7:17 http://www.biomedcentral.com/1471-2393/7/17
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mation to assist in follow-up and analysis will be col-
lected. Women will be asked to complete questionnaires
to assess emotional wellbeing as measured by anxiety
(Spielberger State-Trait Inventory Self Evaluation Ques-
tionnaire [54], and the six-item short form [55]), depres-
sion (Edinburgh Postnatal Depression Scale, [56]),
quality of life (SF36-Health Survey Questionnaire [57]),
the women's preference for either treatment policy and
information about their decision-making process [58].
Treatment Groups
Planned Vaginal Birth After Caesarean Group
Women who plan to have a vaginal birth or are ran-
domised to this care group will await the spontaneous
onset of labour, whilst appropriate. At the time of onset of
labour the woman should be reassessed as to her eligibil-
ity for a planned VBAC. If a complication arises necessitat-
ing caesarean section (eg fetal distress) or if exclusion
criteria for a vaginal birth occur after study entry (eg mal-
presentation or suspected cephalopelvic disproportion
due to increased fetal size) a caesarean should be under-
taken. The guidelines for intrapartum care for women in
the planned VBAC group are based on those recom-
mended by the SOGC [48], ACOG [16], RCOG.) [14,59]
and NICE [50]. Other aspects of care will follow the insti-
tutional guidelines at the hospital. Hospitals agreed to fol-
low the following care recommendations.
Induction of labour
The need for induction of labour for medical or obstetric
indications will be assessed and determined by the obste-
trician caring for the woman. If induction is considered
necessary, this will be performed according to the local
hospital guidelines where the woman has planned to give
birth. The judicious use of oxytocin is not contraindicated
in the presence of a previous caesarean but requires close
monitoring [16]. The guidelines issued by the RCOG on
induction of labour in women with a prior caesarean
highlight a sparsity of data specifically reporting the use of
prostaglandin preparations in women with a previous
caesarean, thereby precluding an ability to make specific
recommendations for clinical care.) [59]. The risk of uter-
ine rupture is higher after an induced labour and highest
after induction with prostaglandins [22]. Prostaglandin E2
gel for induction is therefore not recommended for use for
women in this study.
Augmentation of labour
The judicious use of oxytocin for augmentation of labour
is not contraindicated in the presence of a prior caesarean
section but requires close monitoring [16,48].
Fetal heart rate monitoring
All women undergoing a planned VBAC are advised to
have continuous fetal heart rate monitoring as recom-
mended in the RCOG guidelines for the use of electronic
fetal heart rate monitoring [14]. The presence of a non-
reassuring fetal heart rate tracing will be managed by per-
forming fetal scalp pH sampling when clinically possible,
or emergency caesarean as appropriate [14].
Analgesia/Anaesthesia
Analgesia and anaesthesia should be available according
to the woman's choice. Epidural analgesia may be used as
requested [16].
Planned Elective Repeat Caesarean Group
Women who plan to have an elective repeat caesarean or
are randomised to this care group will have this scheduled
for between 38 weeks and 40 weeks (preferably at 39
weeks), with care provided according to the policy of the
institution involved. The caesarean should be undertaken
with appropriate skill and expertise for surgical proce-
dures and analgesia/anaesthesia. If a woman in the
planned elective repeat caesarean group goes into labour
prior to the scheduled elective surgical procedure, a cae-
sarean will be considered as an emergency according to
the institutional guidelines.
Care during the antenatal period, labour and the postnatal stay of 
both groups
In order to meet the above requirements for care of
women participating in the study, each hospital should be
able to perform continuous fetal heart rate monitoring in
labour, be able to perform fetal scalp pH for an abnormal
fetal heart rate trace, have on-site skilled obstetric, anaes-
thetic and paediatric staff, able to perform emergency cae-
sarean section, have available a consultant obstetrician for
emergency back-up, and be able to cross match blood
[48,49]. Care for the woman and baby will be by the pri-
mary caregivers.
Follow up after birth until the time of primary hospital discharge for 
both groups
After birth information will be obtained relating to birth
and infant outcomes from the woman and infant's case
notes. The birth form will be completed after the woman
has given birth. Similarly the postnatal and neonatal
forms will be completed for live born infants after dis-
charge of both mother and baby from hospital.
Longer-term follow up for both groups:
Longer-term follow up of all women is currently planned
to assess maternal physical and emotional health, wellbe-
ing and child development.
Primary Study Endpoints
Serious adverse outcomes for the infant defined as:BMC Pregnancy and Childbirth 2007, 7:17 http://www.biomedcentral.com/1471-2393/7/17
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Perinatal/Neonatal Mortality (defined as any fetal death
after study entry or death of a liveborn infant within 28
days of age (excluding lethal congenital anomalies); or
Serious neonatal morbidity (defined as one or more of the
following, excluding lethal congenital anomalies: birth
trauma (subdural or intracerebral haemorrhage, spinal
cord injury, basal skull fracture, other fracture, peripheral
nerve injury present at discharge from hospital); seizures
at <24 hours age or requiring two or more drugs to con-
trol; Apgar score <4 at 5 minutes; cord pH<7.18; base def-
icit <-8 (arterial or venous cord blood); neonatal
encephalopathy stage 3 (Sarnat & Sarnat 1976); admis-
sion to the neonatal intensive care unit (NICU) > 4 days;
severe neonatal lung disease (defined as MAP >10 and or
FiO2 >0.80 with need for ventilation); proven necrotising
enterocolitis; proven systemic infection in first 48 hours
of life treated with antibiotics).
Definitions of adverse outcome are those used by the Aus-
tralian and New Zealand Neonatal Network [60] and
those considered by experts as important measures of
term and post-term neonatal morbidity [61].
Secondary Study Endpoints
1. Serious adverse outcome for the woman is defined as
one or more of the following: maternal death; uterine rup-
ture (defined as a clinically significant rupture involving
the full thickness of the uterine wall and requiring surgical
repair); haemorrhage (blood loss of greater than 1500 mL
and/or requiring blood transfusion); hysterectomy for
any complications resulting from birth; vulvar or perineal
haematoma requiring evacuation; deep vein thrombosis
or thrombophlebitis requiring anticoagulant therapy; pul-
monary embolus requiring anticoagulant therapy; pneu-
monia due to infection, aspiration or other causes; adult
respiratory distress syndrome; wound infection (requiring
prolongation of hospital stay or readmission) or wound
dehiscence; damage to the bladder, ureter or bowel requir-
ing repair, or cervical laceration extending to the lower
uterine segment, or abnormal extension of the uterine
incision; occurrence of a fistula involving the genital tract;
bowel obstruction or paralytic ileus; pulmonary oedema;
stroke (defined as acute neurological deficit >24 hours);
cardiac arrest; respiratory arrest; any other serious mater-
nal complication related to birth (as judged by the adverse
events committee, while remaining blinded to group allo-
cation and mode of birth).
Definitions of serious maternal outcomes are based on
those considered as important outcome measures of
maternal morbidity from The Term Breech Trial [62] and
from the ASSHP consensus statement [63].
Sample Size
The incidence of serious adverse infant outcome is the pri-
mary endpoint of the study. The true risk of serious
adverse infant outcome is estimated as 1.6% for planned
elective, repeat caesarean birth [62]. It is proposed that
sufficient women are recruited to provide reliable evi-
dence about the effects of a policy of planned VBAC com-
pared with a policy of planned elective, repeat caesarean
on serious adverse infant outcomes. The sample size will
detect a change in risk from 1.6% to 3.6% as suggested by
the systematic reviews [31]. If the ratio of ERC to VBAC is
1:1 a study of 2180 women would have an 80% power of
detecting a statistically significant difference at an alpha
level of 0.05 (two tailed). Our pilot study has suggested a
ratio of 5.5:4.5. Allowing for an ERC to VBAC ratio of
6.5:3.5 and a small loss to follow up (1%) the sample size
required will be 2314 women.
The expected rate of serious maternal complications for
planned elective repeat caesarean section is likely to be
higher than the 3.9% found in the planned caesarean sec-
tion arm of the Term Breech Trial [62]. Systematic reviews
of the cohort studies of VBAC compared with elective
repeat caesarean section provide an estimate of the risks
for serious maternal complications of 7.7% [31]. A sam-
ple size of 2314 women will have 80% power (2-tailed
alpha error of 0.05) of finding the following increases in
risk for serious maternal complications: 16% to 20.6%,
12% to 16.1%, 8% to 11.5%, 6% to 9.1% and 4% to
6.7%.
Analysis and Reporting of Results
The initial analysis will examine the baseline characteris-
tics of all women in the study, as an indication of compa-
rability of treatment groups. These characteristics will
include maternal age, race, height, weight, smoking his-
tory, vaginal birth prior to caesarean section, indication
for previous caesarean section and treatment preference.
Any differences in these prognostic variables that have
treatment imbalance of sufficient magnitude will be con-
trolled for in subsequent analyses. Log binominal regres-
sion will be used to adjust binary outcomes for
confounders and linear regression for normally distrib-
uted outcomes. Comparison of outcomes for women and
infants will be analysed for the primary and secondary
outcomes on an 'intention to treat' basis, according to
their planned care at recruitment. The relative risks and
95% confidence intervals will be reported for the major
study outcomes, and the number needed to treat to bene-
fit and the number needed to treat to harm will be calcu-
lated.
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